---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-029663"
form_type: "8-K"
ticker: "SSII"
cik: "0001676163"
company_name: "SS Innovations International, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T01:59:55.716963+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avra Medical Robotics enters $3M investment agreement with Dr. Moll convertible into 7% of post-merger equity

## Summary
- Dr. Moll provides additional $1M (total $3M) interim financing for CardioVentures working capital.
- Upon merger close, Moll receives 7% of SSII on fully-diluted basis; Srivastava forfeits 2% of CardioVentures shares.
- If merger not consummated by April 14, 2023, Moll has put right to cash repayment at 7% annual return (12% if late).
- Merger would rename company to SS Innovations International, Inc. (SSII) and combine with CardioVentures.
- Financing priced at $100M pre-money valuation; anti-dilution adjustment if future capital raised below that.

## SEC filing metadata
- accession: 0001213900-23-029663
- form_type: 8-K
- ticker: SSII
- cik: 0001676163
- company_name: SS Innovations International, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676163/000121390023029663/0001213900-23-029663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676163/000121390023029663/ea176767-8k_avramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-029663
- JSON: https://secwatch.observer/filing/0001213900-23-029663.json
- Plain text: https://secwatch.observer/filing/0001213900-23-029663.txt

## Key facts
- Material Agreements
  SS Innovations International, Inc. entered into Investment Agreement with Dr. Frederic Moll valued at $1,000,000 in financing (effective 2023-04-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Dr. Frederic Moll
  - Value: $1,000,000 in financing
  - Effective: 2023-04-07
  source text: On April 7, 2023, we entered into an Investment Agreement (the “ Investment Agreement ”) with Dr. Frederic Moll (“ Dr. Moll ”), pursuant to which, on April 10, 2023, Dr. Moll, in addition to $2,000,000 in financing previously provided to the Company (the “ Initial Investment ”), provided us with an additional $1,000,000 in financing (the “ Additional Investment ,” and together with the Initial Investment, the “ Interim Financing ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676163/000121390023029663/0001213900-23-029663-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.